Nafamostat Gains Ground: 75% Enrollment in NEPHRO CRRT and Favorable KDIGO Guidelines
TLPH has more than doubled off its 52-week low of $0.397.
Summary
Talphera announced 75% enrollment in its NEPHRO CRRT study, positive KDIGO guideline changes for nafamostat, and a 21% larger market estimate, alongside Q2 financial results showing a $4.3 million net loss.
Key Events · Product Development and Regulatory · TLPH
-
NEPHRO CRRT Study 75% Enrolled
The registrational study of nafamostat is 75% enrolled and expected to complete enrollment this year, keeping the company on track for potential FDA submission.
-
KDIGO Guidelines Favor Nafamostat
The draft 2026 KDIGO guidelines now list nafamostat as an acceptable regional anticoagulant during CRRT, a positive change from previous guidelines that could expand its commercial opportunity.
-
Market Opportunity Expanded
Updated market research estimates approximately 200,000 annual U.S. CRRT procedures in 2027, a 21% increase over prior estimates, suggesting a larger addressable market for nafamostat.
-
Financial Position
Cash and investments totaled $17.1 million as of June 30, 2026, with a Q2 net loss of $4.3 million. The company regained Nasdaq compliance with the $1 bid price rule.
Analysis · TLPH · Life Sciences
A significant boost for Talphera's lead product candidate, nafamostat, comes from the draft 2026 KDIGO guidelines, which now list it as an acceptable CRRT anticoagulant. The NEPHRO CRRT study is 75% enrolled and expected to complete this year, while updated market research shows a 21% larger U.S. market than previously estimated. These developments strengthen the commercial case for nafamostat, though the company still faces a going concern warning and limited cash runway.
At the time of this filing, TLPH was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.7M. The 52-week trading range was $0.40 to $1.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.